Department of Anaesthesia, KK Women's and Children's Hospital, 100 Bukit Timah Rd., Singapore 228988.
Anesth Analg. 2011 Oct;113(4):818-25. doi: 10.1213/ANE.0b013e3182289fe9. Epub 2011 Sep 2.
Remifentanil is an ultrashort-acting opioid with favorable pharmacokinetic properties that make it suitable as a labor analgesic. Although it crosses the placenta freely, it is eliminated quickly in the neonate by rapid metabolism and redistribution. We aimed to determine whether remifentanil compared with meperidine is effective in reducing pain scores in laboring parturients. Other effects on the mother, the labor process, and the neonate were also examined.
MEDLINE, CINAHL, Embase, Cochrane CENTRAL, and Maternity and Infant Care databases were searched without language restriction using multiple keywords for labor analgesia, remifentanil, and meperidine. Published abstracts from 5 key research meetings and references from retrieved articles were examined for additional studies. Randomized controlled trials in laboring parturients comparing remifentanil with meperidine were selected. Risk of bias was assessed using criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions. We assessed for adequacy of sequence generation, allocation concealment, blinding, and completeness of follow-up. Data were extracted from each study using a standardized data collection form. The primary outcome was reduction in pain scores (visual analog scale [VAS], 0-100 mm). We also evaluated maternal side effects (sedation, oxygen desaturation, and bradypnea) and effects on the neonate (Apgar scores, umbilical cord pH, and Neurologic and Adaptive Capacity Scores).
Seven studies (349 patients) were identified for inclusion; only 3 studies were suitable for quantitative synthesis in a meta-analysis (233 patients). We found that remifentanil reduces the mean VAS score at 1 hour by 25 mm more than meperidine (P < 0.001) (95% confidence interval = 19-31 mm). Limited conclusions can be made regarding the side-effect profile of remifentanil because of insufficient data.
Compared with meperidine, remifentanil is superior in reducing mean VAS scores for labor pain after 1 hour.
瑞芬太尼是一种超短效阿片类药物,具有良好的药代动力学特性,适合作为分娩镇痛剂。虽然它可以自由穿过胎盘,但在新生儿中,由于快速代谢和重新分布,它很快被消除。我们旨在确定瑞芬太尼与哌替啶相比是否能有效降低分娩产妇的疼痛评分。还检查了对母亲、分娩过程和新生儿的其他影响。
使用多种关键词在无语言限制的情况下,对分娩镇痛、瑞芬太尼和哌替啶进行了 MEDLINE、CINAHL、Embase、Cochrane 中心和母婴护理数据库的搜索。查阅检索文章的已发表摘要和参考文献,以寻找其他研究。选择比较瑞芬太尼与哌替啶的分娩产妇随机对照试验。使用《干预系统评价 Cochrane 手册》中概述的标准评估偏倚风险。我们评估了序列生成、分配隐藏、盲法和随访完整性的充分性。使用标准化数据收集表从每项研究中提取数据。主要结局是疼痛评分(视觉模拟评分[VAS],0-100 毫米)的降低。我们还评估了母亲的副作用(镇静、氧饱和度下降和呼吸过缓)和对新生儿的影响(Apgar 评分、脐静脉 pH 值和神经适应能力评分)。
确定了 7 项研究(349 名患者)纳入研究;只有 3 项研究(233 名患者)适合进行定量合成的荟萃分析。我们发现,瑞芬太尼在 1 小时后使 VAS 评分的平均降低幅度比哌替啶多 25 毫米(P<0.001)(95%置信区间=19-31 毫米)。由于数据不足,对于瑞芬太尼的副作用概况只能得出有限的结论。
与哌替啶相比,瑞芬太尼在 1 小时后降低分娩疼痛的平均 VAS 评分方面更优。